Navigation Links
Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
Date:12/2/2008

Percentage of Biologic-Treated Psoriasis Patients Will Double by 2017, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biologic agents, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will drive the moderate to severe psoriasis drug market to more than double to nearly $5 billion over the next decade.

The new Pharmacor report entitled Psoriasis finds that the overall psoriasis drug market will grow from $2.3 billion in 2007 to $5 billion in 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Following their launches by 2012, the uptake of Stelara and Abbott's ABT-874 will be particularly robust, owing to their novel mechanism of action, durable efficacy and infrequent administration. In 2017, Stelara and ABT-874 will capture 21 percent of sales in the moderate to severe psoriasis market.

Between 2007 and 2017, up to nine biologics will be available to treat psoriasis and the number of biologic-treated patients in the psoriasis market will grow significantly, according to the report. Among patients treated with a systemic drug therapy, the percentage of biologic-treated patients will double, growing from 23 percent in 2007 to 46 percent in 2017.

"With the recent launch of Humira and the highly anticipated launch of Stelara as early as December 2008, we expect a reshuffling to occur in the current order of first-line biologic agents for the treatment of psoriasis," said Joanna Kim, analyst at Decision Resources. "We forecast that Humira and Stelara will join Enbrel as first-line biologics for moderate to severe psoriasis by 2012."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                   Decision Resources, Inc.
    Christopher Comfort                  Elizabeth Marshall
    781-296-2597                         781-296-2563
    ccomfort@dresources.com              emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
2. CVS Caremark Applauds FTCs Leadership on Follow-on Biologics
3. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
4. RTI Biologics Sees Expanded Surgeon User Base of Fresh OC Allografts
5. Biologics Dont Raise Cancer Risk in Rheumatoid Arthritis Patients
6. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
7. Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohns Disease
8. Science Fiction Has Become Reality with Remarkable Anti-Aging Treatment Breakthrough - Turning Back the Biological Clock in Aging
9. Children in Blended Families Still Close to Biological Mothers
10. Biological marker for Alzheimers holds promise for earlier diagnosis and treatment
11. Migraine mutations reveal clues to biological basis of disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... Atlanta, Georgia (PRWEB) , ... February 05, 2016 , ... ... pleased to announce their 2nd Annual No Cost Dental Day to individuals in need. ... 4pm. The purpose of this No Cost Dental Day is to provide dental care ...
(Date:2/5/2016)... ... 05, 2016 , ... Health and wellness is a topic that should concern ... they are experiencing an illness. Migraines are a severe form of a headache and ... would not wish the pain on their worst enemy, the feeling can last for ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... –This week, ... the benefits of having a tankless water heater. To view the report, click ... heaters: tank and tankless. While each has their pros and cons, the type chosen ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  As people age, it ... multitude of recommended screenings and tests that are linked ... priority. However, for the majority of aging individuals, hearing ... planning. For the 37.5 million American adults who report ... present to make hearing health a 2016 healthy aging ...
(Date:2/5/2016)... 2016 http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> http://www.researchandmarkets.com/research/jsc97m/global ... "Global Musculoskeletal Partnering 2010-2016: Deal trends, ... their offering. --> Research ...
(Date:2/5/2016)... --> --> ... the global active pharmaceuticals ingredients (APIs) market stood at ... US$185.9 bn by 2020. It is expected to expand ... The title of the report is "Active Pharmaceutical Ingredients ... by Therapeutic Area) - Global Industry Analysis, Size, Share, ...
Breaking Medicine Technology: